MedTrace Logo

Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

NCT00310544 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2014-12-15

No results posted yet for this study

Summary

The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.

Conditions

Interventions

DRUG

Magnevist (Gadopentetate dimeglumine, BAY86-4882)

One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight

DRUG

Magnevist (Gadopentetate dimeglumine, BAY86-4882)

One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2006-09-30

Countries

  • United States
  • Argentina

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310544 on ClinicalTrials.gov